Anthony Y. Sun net worth and biography

Anthony Sun Biography and Net Worth

Dr. Anthony Y. Sun M.D. serves as Independent Director of the Company. He is involved with many private biotechnology companies. Dr. Sun was at Aisling Capital, a private equity firm dedicated to life sciences, from September 2002 until May 2015, during which he held multiple positions most recently as partner. Dr. Sun currently serves on the board of Immusoft Corporation and he previously served on the board of Versartis, Inc. (NASDAQ: VSAR) from January 2013 to October 2018 when it merged with Aravive Biologics, Inc., and on the board of Senex Biotechnology, Inc. Dr. Sun holds a B.S. in Electrical Engineering from Cornell University, an M.D. from Temple University School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, trained in internal medicine at the Hospital of the University of Pennsylvania and was Board Certified in Internal Medicine.

What is Anthony Y. Sun's net worth?

The estimated net worth of Anthony Y. Sun is at least $27.38 million as of April 4th, 2022. Dr. Sun owns 1,175,589 shares of Zentalis Pharmaceuticals stock worth more than $27,379,468 as of February 5th. This net worth estimate does not reflect any other assets that Dr. Sun may own. Learn More about Anthony Y. Sun's net worth.

What is Anthony Y. Sun's salary?

As the CEO of Zentalis Pharmaceuticals, Inc., Dr. Sun earned a total compensation package of $15,044,399.00 in 2020. Dr. Sun earned a salary of $561,232.00, stock awards of $8,100,645.00, options awards of $5,986,469.00, non-equity compensation of $287,375.00, and other compensation of $108,678.00. Learn More on Anthony Y. Sun's salary.

How do I contact Anthony Y. Sun?

The corporate mailing address for Dr. Sun and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected] Learn More on Anthony Y. Sun's contact information.

Has Anthony Y. Sun been buying or selling shares of Zentalis Pharmaceuticals?

Anthony Y. Sun has not been actively trading shares of Zentalis Pharmaceuticals during the last ninety days. Most recently, Anthony Y. Sun sold 10,471 shares of the business's stock in a transaction on Monday, April 4th. The shares were sold at an average price of $48.50, for a transaction totalling $507,843.50. Following the completion of the sale, the chief executive officer now directly owns 1,175,589 shares of the company's stock, valued at $57,016,066.50. Learn More on Anthony Y. Sun's trading history.

Who are Zentalis Pharmaceuticals' active insiders?

Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Zentalis Pharmaceuticals?

In the last twelve months, insiders at the sold shares 28 times. They sold a total of 257,046 shares worth more than $9,798,239.64. The most recent insider tranaction occured on January, 17th when President Cam Gallagher sold 10,000 shares worth more than $241,500.00. Insiders at Zentalis Pharmaceuticals own 19.9% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.

Information on this page was last updated on 1/17/2023.

Anthony Y. Sun Insider Trading History at Zentalis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/4/2022Sell10,471$48.50$507,843.501,175,589View SEC Filing Icon  
3/1/2022Sell10,471$49.79$521,351.09View SEC Filing Icon  
2/14/2022Sell4,733$50.23$237,738.59View SEC Filing Icon  
2/1/2022Sell10,471$57.58$602,920.18View SEC Filing Icon  
1/3/2022Sell10,471$80.07$838,412.97View SEC Filing Icon  
12/1/2021Sell10,471$77.98$816,528.58View SEC Filing Icon  
11/1/2021Sell10,471$81.44$852,758.24View SEC Filing Icon  
10/4/2021Sell26,799$66.33$1,777,577.67View SEC Filing Icon  
9/1/2021Sell26,794$67.50$1,808,595.00View SEC Filing Icon  
8/2/2021Sell19,015$51.03$970,335.45View SEC Filing Icon  
7/6/2021Sell25,045$46.90$1,174,610.50View SEC Filing Icon  
7/1/2021Sell26,794$51.21$1,372,120.74View SEC Filing Icon  
6/1/2021Sell26,794$54.03$1,447,679.821,423,491View SEC Filing Icon  
5/3/2021Sell26,794$59.32$1,589,420.081,474,161View SEC Filing Icon  
4/5/2021Sell64,562$43.43$2,803,927.661,743,479View SEC Filing Icon  
1/4/2021Sell26,794$52.06$1,394,895.641,804,005View SEC Filing Icon  
12/7/2020Sell35,606$53.52$1,905,633.122,074,567View SEC Filing Icon  
12/4/2020Sell39,769$50.98$2,027,423.622,074,567View SEC Filing Icon  
12/2/2020Sell26,794$51.40$1,377,211.602,116,363View SEC Filing Icon  
11/23/2020Sell15,408$46.53$716,934.242,146,568View SEC Filing Icon  
4/7/2020Buy888$18.00$15,984.002,146,568View SEC Filing Icon  
See Full Table

Anthony Y. Sun Buying and Selling Activity at Zentalis Pharmaceuticals

This chart shows Anthony Y Sun's buying and selling at Zentalis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals logo
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $23.29
Low: $22.94
High: $24.43

50 Day Range

MA: $21.17
Low: $18.07
High: $24.94

2 Week Range

Now: $23.29
Low: $17.33
High: $55.42


353,683 shs

Average Volume

531,366 shs

Market Capitalization

$1.33 billion

P/E Ratio


Dividend Yield